文献速递慢阻肺

GLP-1受体激动剂与2型糖尿病患者慢阻肺急性加重风险的关联

Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究基于美国一医疗系统2012至2022年的电子健康记录,采用活性对照新使用者设计,纳入1642例慢阻肺合并2型糖尿病患者,比较GLP-1受体激动剂与其他降糖药对慢阻肺急性加重的影响。结果显示,与DPP-4抑制剂和磺脲类药物相比,GLP-1受体激动剂使用者的急性加重率显著更低,但与SGLT2抑制剂使用者相比无显著差异。

要点

  • 与DPP-4抑制剂和磺脲类相比,GLP-1受体激动剂与更低的慢阻肺急性加重率相关
  • GLP-1受体激动剂与SGLT2抑制剂在急性加重结局上无显著差异
  • 需前瞻性研究验证并阐明降糖药与慢阻肺急性加重关联的机制

核心结论

  • 在慢阻肺合并2型糖尿病患者中,GLP-1受体激动剂使用与其他降糖药相比与更低的急性加重率相关,但需前瞻性研究验证。

研究设计与样本

  • 回顾性、观察性、基于电子健康记录的研究,采用活性对照新使用者设计,纳入美国一医疗系统2012至2022年的1642例慢阻肺患者。
  • 慢阻肺队列通过既往验证的机器学习算法识别,该算法包含自然语言处理工具。
  • 暴露定义为GLP-1受体激动剂(参照组)、DPP-4抑制剂、SGLT2抑制剂或磺脲类药物的处方。

主要发现

  • 未调整的慢阻肺急性加重计数在GLP-1受体激动剂使用者中更低。
  • 调整后急性加重率在DPP-4抑制剂使用者中显著高于GLP-1受体激动剂使用者(发生率比1.48,95%CI 1.08-2.04;P=0.02)。
  • 调整后急性加重率在磺脲类使用者中显著高于GLP-1受体激动剂使用者(发生率比2.09,95%CI 1.62-2.69;P<0.0001)。
  • GLP-1受体激动剂使用与DPP-4抑制剂和磺脲类使用相比,与显著降低的重度急性加重风险相关;与磺脲类使用相比,与降低的中度急性加重风险相关。
  • 调整临床协变量后,GLP-1受体激动剂使用者的中度急性加重风险也低于DPP-4抑制剂使用者;GLP-1受体激动剂与SGLT2抑制剂使用者之间急性加重结局无统计学显著差异。

临床怎么用

  • 对于慢阻肺合并2型糖尿病患者,选择降糖方案时可考虑GLP-1受体激动剂以可能降低慢阻肺急性加重风险,但需结合个体情况并等待前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Patients with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D) have worse clinical outcomes compared with patients without metabolic dysregulation. GLP-1 (glucagon-like peptide 1) receptor agonists (GLP-1RAs) reduce asthma exacerbation risk and improve FVC in patients with COPD. Objectives: To determine whether GLP-1RA use is associated with reduced COPD exacerbation rates, and severe and moderate exacerbation risk, compared with other T2D therapies. Methods: A retrospective, observational, electronic health records-based study was conducted using an active comparator, new-user design of 1,642 patients with COPD in a U.S. health system from 2012 to 2022. The COPD cohort was identified using a previously validated machine learning algorithm that includes a natural language processing tool. Exposures were defined as prescriptions for GLP-1RAs (reference group), DPP-4 (dipeptidyl peptidase 4) inhibitors (DPP-4is), SGLT2 (sodium-glucose cotransporter 2) inhibitors, or sulfonylureas. Measurements and Main Results: Unadjusted COPD exacerbation counts were lower in GLP-1RA users. Adjusted exacerbation rates were significantly higher in DPP-4i (incidence rate ratio, 1.48 [95% confidence interval, 1.08-2.04]; P = 0.02) and sulfonylurea (incidence rate ratio, 2.09 [95% confidence interval, 1.62-2.69]; P < 0.0001) users compared with GLP-1RA users. GLP-1RA use was also associated with significantly reduced risk of severe exacerbations compared with DPP-4i and sulfonylurea use, and of moderate exacerbations compared with sulfonylurea use. After adjustment for clinical covariates, moderate exacerbation risk was also lower in GLP-1RA users compared with DPP-4i users. No statistically significant difference in exacerbation outcomes was seen between GLP-1RA and SGLT2 inhibitor users. Conclusions: Prospective studies of COPD exacerbations in patients with comorbid T2D are warranted. Additional research may elucidate the mechanisms underlying these observed associations with T2D medications.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Foer, Strasser, Cui, et al. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes. Am J Respir Crit Care Med. 2023. PMID: 37647574. doi:10.1164/rccm.202303-0491OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。